WallStreetZenWallStreetZen

NASDAQ: BCYC
Bicycle Therapeutics PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BCYC

Based on 6 analysts offering 12 month price targets for Bicycle Therapeutics PLC

Min Forecast
$10.00+38.5%
Avg Forecast
$16.67+130.84%
Max Forecast
$44.00+509.42%

Should I buy or sell BCYC stock?

Based on 6 analysts offering ratings for Bicycle Therapeutics PLC.

Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 50%
Hold
3 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BCYC's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates BCYC as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their BCYC stock forecasts and price targets.

BCYC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-24
lockedlocked$00.00+00.00%2025-10-31
lockedlocked$00.00+00.00%2025-10-31
lockedlocked$00.00+00.00%2025-08-12
lockedlocked$00.00+00.00%2025-08-12
Oppenheimer
Top 4%
97
BuyMaintains$44.00+509.42%2025-08-11

1 of 1

Forecast return on equity

Is BCYC forecast to generate an efficient return?

Company
-16.93%
Industry
347.61%
Market
205.38%
BCYC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BCYC forecast to generate an efficient return on assets?

Company
-13.71%
Industry
120.24%
BCYC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BCYC earnings per share forecast

What is BCYC's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
-$3.83
Avg 2 year Forecast
-$3.61
Avg 3 year Forecast
-$2.54

BCYC revenue forecast

What is BCYC's revenue in the next 3 years based on estimates from 16 analysts?

Avg 1 year Forecast
$31.4M+10.97%
Avg 2 year Forecast
$50.0M+76.34%
Avg 3 year Forecast
$190.2M+571.12%
BCYC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BCYC revenue growth forecast

How is BCYC forecast to perform vs Biotechnology companies and vs the US market?

Company
80.12%
Industry
113.66%
Market
23.31%
BCYC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BCYC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BCYC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCYC$7.22$16.67+130.84%Buy
NAGE$6.28$13.00+107.01%Strong Buy
ZVRA$9.08$22.00+142.29%Strong Buy
IVVD$2.21$8.00+261.99%Strong Buy
OCGN$1.65$7.00+324.24%Strong Buy
View Top Biotech Stocks

Bicycle Therapeutics Stock Forecast FAQ

Is Bicycle Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: BCYC) stock is to Buy BCYC stock.

Out of 6 analysts, 0 (0%) are recommending BCYC as a Strong Buy, 3 (50%) are recommending BCYC as a Buy, 3 (50%) are recommending BCYC as a Hold, 0 (0%) are recommending BCYC as a Sell, and 0 (0%) are recommending BCYC as a Strong Sell.

If you're new to stock investing, here's how to buy Bicycle Therapeutics stock.

What is BCYC's earnings growth forecast for 2026-2028?

(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.89%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.83%.

Bicycle Therapeutics's earnings in 2026 is -$250,660,000.On average, 15 Wall Street analysts forecast BCYC's earnings for 2026 to be -$265,942,640, with the lowest BCYC earnings forecast at -$340,582,496, and the highest BCYC earnings forecast at -$177,720,550. On average, 14 Wall Street analysts forecast BCYC's earnings for 2027 to be -$250,418,105, with the lowest BCYC earnings forecast at -$367,094,906, and the highest BCYC earnings forecast at -$165,338,380.

In 2028, BCYC is forecast to generate -$176,416,433 in earnings, with the lowest earnings forecast at -$278,720,206 and the highest earnings forecast at -$69,194,476.

What is BCYC's revenue growth forecast for 2026-2028?

(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of 80.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.31%.

Bicycle Therapeutics's revenue in 2026 is $28,339,000.On average, 16 Wall Street analysts forecast BCYC's revenue for 2026 to be $2,181,481,593, with the lowest BCYC revenue forecast at $212,751,337, and the highest BCYC revenue forecast at $4,370,177,448. On average, 15 Wall Street analysts forecast BCYC's revenue for 2027 to be $3,466,452,499, with the lowest BCYC revenue forecast at $197,143,560, and the highest BCYC revenue forecast at $9,127,427,756.

In 2028, BCYC is forecast to generate $13,193,080,140 in revenue, with the lowest revenue forecast at $2,719,221,523 and the highest revenue forecast at $28,709,291,118.

What is BCYC's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BCYC) forecast ROA is -13.71%, which is lower than the forecast US Biotechnology industry average of 120.24%.

What is BCYC's Price Target?

According to 6 Wall Street analysts that have issued a 1 year BCYC price target, the average BCYC price target is $16.67, with the highest BCYC stock price forecast at $44.00 and the lowest BCYC stock price forecast at $10.00.

On average, Wall Street analysts predict that Bicycle Therapeutics's share price could reach $16.67 by Nov 24, 2026. The average Bicycle Therapeutics stock price prediction forecasts a potential upside of 130.84% from the current BCYC share price of $7.22.

What is BCYC's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BCYC) Bicycle Therapeutics's current Earnings Per Share (EPS) is -$3.62. On average, analysts forecast that BCYC's EPS will be -$3.83 for 2026, with the lowest EPS forecast at -$4.91, and the highest EPS forecast at -$2.56. On average, analysts forecast that BCYC's EPS will be -$3.61 for 2027, with the lowest EPS forecast at -$5.29, and the highest EPS forecast at -$2.38. In 2028, BCYC's EPS is forecast to hit -$2.54 (min: -$4.02, max: -$1.00).

What is BCYC's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BCYC) forecast ROE is -16.93%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.